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Vaccine2 Recommended Groups for Vaccination 
DTaP 1. All children younger than 7 years of age 
Note: DTaP vaccine is not licensed for individuals 7 years of age or older 
DT 1. Children less than 7 years of age with true and valid contraindications to pertussis 
vaccine 
 
 
 
 
 
 
 
 
Hepatitis A 
1. All children 12 through 23 months of age. 
2. Catch-up of unvaccinated children 2 through 18 years of age.  Such programs 
might be warranted if there are ongoing outbreaks among children or adolescents. 
3. High-risk individuals including: 
• Men who have sex with men 
• Users of injection and illicit drugs 
• Persons with chronic liver disease, including hepatitis C 
• Persons with clotting factor disorders 
• Persons working with hepatitis A virus (HAV) in a research laboratory or with 
HAV infected primates.   No other occupations have been demonstrated to 
increase the risk of HAV infection.   
• Persons traveling to, or working in, anywhere EXCEPT the U.S., Western 
Europe, New Zealand, Australia, Canada, and Japan.  Persons 2 years of age 
and older who live in communities experiencing outbreaks of HAV (if 
indicated by local epidemiologic data). 
• Persons in close contact with an international adoptee during the first 60 days 
after arrival in the U.S. from a country of high or intermediate endemicity. 
4. All other persons seeking protection from HAV infection. 
5.   Post-exposure for healthy persons 12 months through 40 years of age, given 
within 14 days of exposure. (For persons older than 40 years of age: immune 
globulin (IG) is preferred post exposure, vaccine can be used if IG is not 
available. Children less than 12 months, immunocompromised individuals, those 
with chronic liver disease who have contraindications for hep A vaccine, should 
receive IG post exposure). 
1The information in this table is a summary of the Advisory Committee on Immunization Practices (ACIP) 
recommendations.  Complete ACIP recommendations for each vaccine, including the number of doses to be administered 
and the timing of doses, can be accessed at the ACIP website http://www.cdc.gov/vaccines/acip/index.html 
2 Licensed combination vaccines may be used whenever any components of the combination are indicated 
and other components of the vaccine are not contraindicated and if approved by the FDA for that dose of the 
series.  Package inserts for all approved vaccine formulations can be found at: 
http://www.fda.gov/BiologicsBloodVaccines/vaccines/ApprovedProducts/ucm093830.htm 
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Hepatitis B 
1. Routine Pediatric and Adolescent Recommendations 
• Infants born to mothers who are hepatitis B surface antigen (HBsAg)-positive. 
• All infants. 
• All unvaccinated children and adolescents less than 19 years of age. 
2.  Adult Recommendations 
a. Persons at risk for infection by sexual exposure: 
• Sex partners of HBsAg-positive persons. 
• Sexually active persons not in a long-term, mutually monogamous 
relationship (e.g., persons with more than one sex partner during the 
previous 6 months). 
• Persons seeking evaluation or treatment for a sexually transmitted disease. 
• Men who have sex with men. 
b. Persons at risk for infection by percutaneous or mucosal exposure to blood: 
• Current or recent injection-drug users. 
• Household contacts of HBsAg-positive persons. 
• Residents and staff of facilities for developmentally disabled persons. 
• Health-care and public safety workers with reasonably anticipated risk for 
exposure to blood or blood-contaminated body fluids. (Note: Employers 
covered by federal OSHA regulations are responsible for supplying hepatitis 
B vaccine to their at-risk employees.) 
• Persons with end-stage renal disease, including predialysis, hemodialysis, 
peritoneal dialysis, and home dialysis patients. 
c. Other: 
• International travelers to regions with high or intermediate levels (HBsAg 
prevalence of >2%) of endemic hepatitis B virus (HBV) infection. 
• Persons with chronic liver disease. 
• Persons with diabetes < 60 years as soon as feasible after diagnosis. 
• Persons with diabetes > 60 years at clinician’s discretion, considering:  1) 
need for assisted blood glucose monitoring in long-term care facilities;                  
2) likelihood of acquiring hepatitis B infection and its complications or 
chronic sequelae; and 3) likelihood of immune response to immunization. 
• Persons with HIV infection. 
• All other persons seeking protection from HBV infection. 
d. High risk settings: (Settings where vaccination is recommended for all adults, 
because a high proportion of individuals have risk factors.) 
• STD treatment facilities. 
• HIV testing and treatment facilities. 
• Facilities providing drug-abuse treatment and prevention services. 
• Health-care settings providing services for injection-drug users or men who 
have sex with men. 
• Correctional facilities. 
• End-stage renal disease programs and facilities for chronic hemodialysis 
patients. 
• Institutions and nonresidential daycare facilities for persons with 
developmental disabilities. 
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Hib 
1. All children younger than 5 years of age.   
• The number of doses needed to complete the schedule depends on the age of the child 
and the formulation used 
2.  Hib vaccine is not routinely recommended for those 5 years and older unless they are 
considered to be at high risk for invasive Hib disease. Groups at high risk include:  sickle 
cell disease, functional or anatomic asplenia, leukemia, malignant neoplasms, other 
immunocompromising conditions, HIV infected children 
3.  Recommendations for high risk groups are as follows; 
• Age <12 months: follow routine schedule. 
• Age 12-59 months: 
• If unimmunized or received 0 or 1 dose before 12 months, they should receive 2 
doses 8 weeks apart; 
• If received >2 doses before age 12 months, they should receive 1 dose 8 weeks after 
last dose; 
• If completed a primary series and received a booster dose at ≥12 months, no 
additional doses are needed. 
• Age younger than 5 years undergoing chemotherapy or radiation: 
• If routine Hib doses administered >14 days before starting therapy, revaccination is 
not required; 
• If a Hib dose is administered < 14 days before starting therapy or given during 
therapy, repeat those doses starting at least 3 months following therapy completion. 
• Age >15 months undergoing elective splenectomy: if unimmunized, give 1 dose >2 
weeks prior to procedure. 
• Asplenic children 5 years and older and adults: if unimmunized, give 1 dose (if 
undergoing procedure give >2 weeks prior). 
• Hematopoietic stem cell transplants of all ages and regardless of Hib vaccination 
history: 3 doses (at least 4 weeks apart) are recommended beginning 6-12 months after 
transplant.   
• HIV infected children:  1 dose of Hib vaccine is recommended for previously 
unvaccinated children 5 through 18 years of age with HIV infection.  But, it is no 
longer recommended for previously unvaccinated HIV infected adults. 
Human 
Papillomavirus  
 
9-valent 
(9vHPV) 
(Gardasil 9) 
 
4-valent 
(4vHPV) 
Gardasil 
2-valent 
(2vHPV) 
Cervarix 
 
1. All females and males entering 7th grade (11-12 years of age).  The vaccination series 
can be started in females and males as young as 9 years of age.  
2. Routine “catch-up” vaccination for all females 13 through 26 years of age. 
3. Routine “catch-up” vaccination for males 13 through 21 years of age. 
4. “Catch-up” vaccination for high risk males 22 through 26 years of age 
(immunosuppressed, men who have sex with men, HIV-infected). 
5. Permissive “catch-up” for non-high risk males 22-26 years. 
6. HPV vaccine is recommended for all females and males through 26 years who are 
immunocompromised who did not get the vaccine when they were younger. 
Note: 9vHPV and 4vHPV vaccines are approved for use in both females and males.  
2vHPV vaccine is only approved for use in females. 
 
acip-summary-recommended-groups 4 
 
 
 
 
 
 
 
 
Influenza 
 
 
Inactivated 
Influenza 
Vaccine (IIV) 
 
Live Attenuated 
Influenza 
Vaccine 
(LAIV) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. All persons aged 6 months and older every year 
• Children aged 6 months through 8 years who have previously received 2 or more doses 
of trivalent or quadrivalent influenza vaccine as of July 1, 2015, need only 1 dose for 
the 2015-2016 season.  The 2 previous doses do not need to have been given during the 
same season or consecutive seasons.  For additional guidance on doses needed for 
children < 9 years of age, follow the 2015-16 guidance at: 
http://www.cdc.gov/vaccines/acip/index.html 
• This year, there is no preferential recommendation for any one age-appropriate 
approved flu formulation over another.  The ACIP did not renew its preferential 
recommendation for influenza vaccine (LAIV) for use in healthy children 2-8 years of 
age. Vaccination should not be delayed for a specific vaccine preparation. 
 
2. People at increased risk for influenza-related complications: 
• All children 6 months through 4 years of age. 
• All persons > 50 years of age. 
• People 6 months - 18 years of age who are receiving long-term aspirin therapy.  
• Women who will be pregnant during influenza season and postpartum women. 
• People > 6 months of age who have: 
• Chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, 
hepatic, neurological, hematologic, or metabolic disorders, including diabetes; 
• Immunosuppression (includes  immunosuppression caused by medications or HIV); 
• Any condition (e.g., cognitive dysfunction, spinal cord injuries, seizure disorders, or 
other neuromuscular disorders) that can compromise respiratory function or the 
handling of respiratory secretions or that can increase the risk of aspiration. 
• Residents of nursing homes and other chronic-care facilities. 
• American Indians/Alaska Natives  
• People who are morbidly obese (BMI > 40)  
3. Persons who can transmit influenza to persons at high risk: 
• Health care personnel (HCP), employees of assisted living facilities, people who 
provide home care to people at risk, medical emergency response workers, and students 
in these professions. 
• Household contacts (including children) and caregivers of children aged < 5 years and 
adults > 50 years, and contacts of people at risk for complications from flu (listed 
above).   
4. Persons at increased risk of exposure to influenza: 
• Persons who provide essential community services. 
• Students and other persons in institutional settings (e.g., dormitories).  
• Certain travelers. 
 
Note: For most healthy, non pregnant persons, either LAIV or IIV may be used.  LAIV should 
not be used for those who are pregnant, immunosuppressed, have asthma or any other medical 
condition that predisposes them to influenza complications. 
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Meningococcal 
Quadrivalent  
(MenACWY) 
Vaccines 
 
Meningococcal 
Conjugate vaccine 
(MCV4): 
Menactra licensed 
for ages 9 months 
through 55 years, 
Menveo licensed 
for 2 months 
through 55 years 
 
Meningococcal 
Polysaccharide 
vaccine (MPSV4): 
licensed for ages 2 
years and older 
 
  
1. All adolescents 11 through 18 years of age. 
• One dose routinely administered at 7th grade entry (11-12 years of age)  
• Booster dose for those 16 - 18 years of age (minimum interval between doses is 8 
weeks) 
• Routine catch-up of adolescents 13 through 18 years of age who have not  received a 
1st dose meningococcal vaccine (No booster if primary dose received on or after 16 
years of age years) 
2. College freshmen through age 21 years  
• One dose of MCV no more than 5 years before enrollment in college, particularly if 
they are new residential students 
• One booster dose before enrollment if they received their primary dose prior to age 16 
years  
3. Persons with risk for exposure: travelers to countries where meningococcal disease is 
hyperendemic or epidemic, military recruits and microbiologists working with N. 
meningitidis. 
• One dose if not previously vaccinated 
• Booster at >3 years for children aged 2 through 6 years; booster at >5 years for persons 
aged 7 years and older, if they remain at risk 
4.   High risk children 2-23 months of age who:  have persistent complement component 
deficiencies; functional or anatomic asplenia (including sickle cell); are travelers to 
countries where meningococcal disease is hyperendemic or epidemic; or live in 
communities or institutions where outbreaks are occurring: 
• Primary series: 2 - 4 doses, depending on age and formulation (see ‘Note’ below). 
• Give boosters at >3 years for children aged 2 through 6 years; and at > 5 years for 
persons aged 7 years and older 
5.   Persons > 2 years with persistent complement deficiency or anatomic asplenia (including 
those with sickle cell) 
• Primary series: 2 doses, 2 months apart 
• Separate PCV13 and MCV4 by > 4 weeks 
• Give boosters at >3 years for children aged 2 through 6 years; at >5 years for persons 
aged 7 years and older 
6.   HIV-infected persons older than age 2 years, if they have another indication for 
meningococcal vaccines  
• Primary series: 2 doses, 2 months apart 
• Give boosters at >3 years for children aged 2 through 6 years; at >5years for persons 
aged 7 years and older 
7.   Persons who wish to decrease their risk for meningococcal disease may elect to be 
vaccinated. 
Note: Because of the high risk for invasive pneumococcal disease, children with functional and 
anatomic asplenia (including sickle cell disease) should NOT be immunized with Menactra 
before 2 years -- and it should be separated by >4 weeks after completion of all PCV13 doses 
to avoid potential interference with immune response to PCV13.  These children can and 
should receive Menveo. 
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Meningococcal 
B (MenB) 
Vaccines 
 
MenB-FHbp 
(Trumenba) 
MenB-4C 
(Bexsero) 
 
1. Persons aged ≥10 years who are at increased risk for meningococcal disease due to 
serogroup B: 
• Persons with persistent complement component deficiencies (including: inherited or 
chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or taking eculizumab 
[Soliris®]). 
• Persons with anatomic or functional asplenia (including: sickle cell). 
• Microbiologists routinely exposed to isolates of Neisseria meningitidis. 
• Persons identified as at increased risk because of a serogroup B meningococcal 
disease outbreak as determined public health authorities. 
(The above recommendation is a Category A recommendation which means MenB vaccine 
is recommended for everyone in these high risk groups.) 
2. In addition, MenB vaccine series may be administered to adolescents and young adults 16 
through 23 years of age to provide short term protection against most strains of serogroup B 
meningococcal disease.  The preferred age for MenB vaccination in this age group is 16 
through 18 years of age in order to maximize protection during the highest risk period.  
(This is a Category B recommendation which means that it allows for individual clinical 
decision making.) 
Vaccine Schedules 
• Bexsero (MenB-4C) should be administered as a 2-dose series (0, >1 month). 
• Trumenba (MenB-FHbp) should be administered as a 3-dose series (0, 2, 6 months). 
• The same vaccine product must be used for all doses. 
• MenB-FHbp or MenB-4C may be administered concomitantly with MenACWY vaccines 
and other adolescent vaccines, but at a different anatomic site, if feasible. 
 
MMR  
1. All children 12 months through 18 years of age. 
• The 1st dose is routinely administered at 12 through 15 months of age. 
• The 2nd dose is routinely administered at kindergarten entry (4-6 years of age). 
• A 2nd dose “catch-up” for all children and adolescents who previously received 1 dose. 
2. For children 6-11 months with international travel, administer 1 dose.  These children 
should be revaccinated at age 12-15 months.  If remain in area that is high risk, revaccinate 
at 12 months, with a 2nd dose > 4 weeks later. 
3. All individuals 19 years of age and older, who were born in or after 1957: 1 dose  
4. All people aged ≥ 12 months with HIV infection who do not have evidence of MMR 
immunity or evidence of severe immunosuppression. 
5. Adults at high risk (i.e., persons who work in health-care facilities, international travelers, 
and students at post-high school educational institutions): 2 doses 
6. All health-care workers: 2 doses are recommended, regardless of year of birth 
7. Women of childbearing age without documented vaccination or laboratory evidence of 
immunity  
8. Any contact of a suspect or confirmed case > 12 months without documentation of 2 doses 
of MMR vaccine.  For infants aged 6 through 11 months, MMR vaccine can be 
administered in place of IG, if administered within 72 hours of exposure.  Such infants 
must receive a normal 2-dose series beginning ≥12 months. 
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Pneumococcal 
Conjugate 
(PCV13) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Healthy children younger than 5 years of age should complete 4-dose PCV13 series. 
2. Healthy children aged 24 through 59 months with any incomplete PCV (PCV7 or PCV13) 
schedule before age 24 months: 1 dose of PCV13 
3. Children 24 through 71 months of age with underlying medical conditions (including 
chronic medical conditions, CSF fluid leaks, cochlear implants, immunocompromising 
conditions, HIV, sickle cell, asplenia): 
• Unvaccinated or any incomplete schedule of <3 doses of PCV13:  2 doses of PCV13 
given 8 weeks after most recent PCV dose and 8 weeks apart. 
• Any incomplete schedule of 3 doses of PCV13:  1 dose of PCV13 > 8 weeks after most 
recent PCV dose. 
4. A single dose of PCV13 is recommended for children 6 through 18 years of age and adults 
> 19 years of age who have never been vaccinated with: 
a. Functional or anatomic asplenia 
b. HIV infection or other immunocompromising conditions 
c. Cochlear implant 
d. Cerebrospinal fluid leak 
5. A single dose is recommended for  all adults 65 years of age or older: 
• A dose of PCV13 followed by PPSV23 should be administered routinely in a series to 
all immunocompetent adults aged ≥65 years.  PCV13 should be administered only once 
for all adults.  Specific recommendations are based on a person’s previous 
pneumococcal vaccine history. 
• Persons who are pneumococcal vaccine-naïve.  Adults aged ≥65 years who have 
not previously received pneumococcal vaccine or whose previous vaccination 
history is unknown should receive a single dose of PCV13 first, followed by a dose 
of PPSV23.  The dose of PPSV23 should be given >1 year after a dose of PCV13. 
If PPSV23 cannot be given during this time window, the dose of PPSV23 should 
be given during the next visit.   
• Persons previously vaccinated with PPSV23.  Adults aged ≥65 years who have 
previously received ≥1 doses of PPSV23 also should receive a single dose of 
PCV13 if they have not yet received it.  A dose of PCV13 should be given ≥1 year 
after receipt of the most recent PPSV23 dose.  For those for whom an additional 
dose of PPSV23 is indicated, this subsequent PPSV23 dose should be given >1 
year after PCV13 and >5 years after the most recent dose of PPSV23. 
Timing: 
• The two vaccines should not be co-administered.  If doses of PPSV23 and PCV13 are 
inadvertently given on the same day or earlier than the recommended interval, those doses 
do not need to be repeated. 
• Adults 19 years and older at increased risk for pneumococcal disease who received a dose 
of PCV13 at 64 years or younger should not receive another dose of PCV13 at 65 years or 
older. 
• For adults >65 years with immunocompromising conditions, functional or anatomic 
asplenia, CSF fluid leaks or cochlear implants, the recommended interval between a dose of 
PCV13 and PPSV23 remains at >8 weeks.   
Note:  For additional information on the appropriate intervals, including when PPSV23 is given 
before PCV13, see the section on timing under PPSV23 vaccine below. 
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Pneumococcal 
Polysaccharide 
(PPSV23) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. All adults 65 years of age and older. 
2. Persons 2 through 64 years of age: 
• With chronic illnesses, including cardiovascular disease, pulmonary disease, diabetes, 
alcoholism, liver disease, renal failure or nephrotic syndrome and CSF fluid leaks. 
• With anatomic or functional asplenia (e.g., sickle cell disease and other 
hemoglobinopathies, congenital or acquired asplenia, splenic dysfunction, or 
splenectomy). 
• Who have or are scheduled to have cochlear implants. 
• Who are immunocompromised, including those with congenital immunodeficiency, 
HIV infection, leukemia, lymphoma, multiple myeloma, Hodgkin disease, generalized 
malignancy, organ or bone marrow transplantation and those with immunosuppression 
caused by chemotherapy, radiation therapy or high-dose, long-term corticosteroids 
(including children with asthma on long-term corticosteroids).  
• Who live in long-term care facilities 
3. Persons 19 years of age and older with asthma 
4. Persons 19 years of age and older who smoke 
5. In special situations, public health authorities may recommend PPSV23 for some groups of 
Alaska Natives and American Indian children 24 through 59 months of age and adults 50 
through 64 years of age 
One time revaccination after five years for: 
• People aged 19 through 64 years of age with: 
• Functional or anatomic asplenia (including sickle cell disease) 
• Immunocompromising conditions (including HIV infection) 
• Chronic renal failure or nephrotic syndrome in adults 
• People aged > 65, if they were vaccinated 5 or more years previously, and were aged younger 
than 65 years at the time of the previous dose 
• No further doses needed for those vaccinated at > 65 years 
 
Timing of vaccination for ‘special highest risk’ children 2-18 years and adults >19 years 
who are recommended to receive both PCV13 and PPSV23 (functional or anatomic 
asplenia, sickle cell, HIV infection, immunocompromising conditions, chronic renal failure 
or nephrotic syndrome, CSF fluid leaks, cochlear implants) are outlined below: 
• For the ‘special highest risk’ of all ages ideally administer PCV13 first and then administer 
PPSV23 at least 8 weeks later.  This interval minimized the risk window for invasive 
pneumococcal disease caused by serotypes unique to PPSV23 in these highly vulnerable 
groups. 
• If the individual is 2-18 years of age and has already received PPSV23, administer 
PCV13 at least 8 weeks later. 
• If the individual is >19 years and has already received PPSV23, administer PCV13 at 
least 1 year later. 
• When cancer chemotherapy, other immunosuppressive therapy or splenectomy is being 
considered, please vaccinate > 2 weeks before.  Vaccination during chemotherapy or 
radiation therapy should be avoided. 
• The PPSV23 and PSV13 should not be co-administered.  If doses of PPSV23 and PCV13 
are inadvertently given on the same say or earlier than the recommended interval, those 
doses should not be repeated. 
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Inactivated 
Polio 
(IPV) 
 
 
 
 
 
1. 4-dose series for children less than 18 years of age 
Administer the final dose in the IPV series at age ≥4 years regardless of the number of 
previous doses and at least > 6 months after the previous dose. 
• A 4th dose is not necessary if the 3rd dose was administered at ≥4 years and at least > 6 
months after the previous dose. 
• If both OPV and IPV were administered as part of the series, a total of 4 doses should 
be administered, regardless of child’s age. 
2. Vaccination of adults in the following high-risk groups is recommended with a 3-dose 
series.  Routine poliovirus vaccination of adults (i.e., persons aged >18 years) residing in 
 the United States is not necessary. 
Those traveling to areas with endemic or epidemic polio. 
• Laboratory workers who handle poliovirus.  
• Healthcare workers caring for polio patients. 
Rotavirus 
All infants 6 weeks through 8 months 0 days of age. 
Note: Rotavirus vaccine is not licensed for use in infants older than 8 months 0 days of age. 
Td 
1. Persons aged 7 years and older without a primary series of tetanus-diphtheria containing 
vaccine.* 
2. A booster dose every 10 years.* 
3. Wound management of those 7 years of age and older.* 
4. Persons traveling to countries at high risk for diphtheria.* 
5. Pregnant women who are under-immunized. 
6. Those at occupational risk who are under-immunized.* 
*Substitute 1 dose of Tdap for Td. 
Note: Td vaccine is not licensed for use in individuals less than 7 years of age. 
 
 
 
 
 
 
Tdap 
 
 
 
 
Boostrix 
licensed for ages 
> 10 years of 
age 
 
Adacel licensed 
for ages 10-64 
years of age 
 
 
 
 
Tdap is recommended for use as a single booster dose except in pregnant women.   
1. Adolescents (10 through 18 years of age).  Substitute 1 dose of Tdap for Td in: 
• All adolescents entering 7th grade (11-12 years of age). 
• Adolescents 13 through 18 years of age who have not yet received a dose of Tdap. 
• Children 7 -10 years of age who are not fully vaccinated against pertussis* and for 
whom no contraindication to pertussis vaccine exists should receive a single dose of 
Tdap.   
• Children 7 - 10 years of age who have never been vaccinated against tetanus, diphtheria, 
or pertussis or who have unknown vaccination status should receive a series of three 
vaccinations containing tetanus and diphtheria toxoids.  The first of these three doses 
should be Tdap. 
• Individuals who are un- or under-vaccinated for wound prophylaxis, including 
pregnant teens. 
• Individuals who have been exposed to pertussis or in an outbreak setting. 
Fully vaccinated is defined as 5 doses of DTaP or 4 doses of DTaP, if the fourth dose was      
administered on or after the fourth birthday 
 
2. Adults (≥ 19 years of age).  A single dose of Tdap to replace a single dose of Td. 
• Special emphasis on adults with close contact with infants less than 12 months of age, 
including those >65 years.                              
                                                                                         (Continued on next page) 
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Tdap 
Continued 
 
• Parents, particularly in the postpartum period. 
• Grandparents 
• Child care workers. 
• Health-care providers 
• Individuals un- or under-vaccinated for wound prophylaxis, including pregnant 
women. 
• Individuals who have been exposed to pertussis or in an outbreak setting. 
3. Pregnant women. Tdap should be administered during each pregnancy, irrespective of the 
patient’s history of receiving Tdap.  To maximize antibody transfer to the infant, administer 
Tdap between 27 and 36 weeks gestation, although Tdap may be given any time during 
pregnancy.  If not administered during pregnancy, Tdap should be administered 
immediately postpartum for women not previously vaccinated with Tdap. 
Note:  Administer Tdap regardless of interval since last tetanus- or diphtheria-toxoid vaccine. 
Do not miss an opportunity to vaccinate persons > 65 years.  ACIP recommends permissive use 
of Adacel, if Boostrix not available for this age group 
Varicella 
1.  All preschool and school-aged children: 2 doses of varicella-containing vaccine 
• The 1st dose routinely administered at 12 through 15 months of age. 
• The 2nd dose routinely administered at kindergarten entry (4 through 6 years of age). 
2.  Children, adolescents and adults without evidence of immunity to varicella: 2 doses of 
varicella vaccine. 
3.  A 2nd dose “catch-up” vaccination is recommended for children, adolescents, and adults 
who previously had received 1 dose. 
4.  Susceptible contacts of confirmed or suspect cases of varicella, including those who have 
previously received only 1 dose. 
Give special consideration to: 
• Susceptible health-care workers. 
• Susceptible postpartum women and non-pregnant women of child-bearing age   
• Susceptible child care providers, teachers of young children, residents/staff in 
institutional settings, including correctional facilities. 
• Susceptible college students and military personnel. 
• Susceptible contacts of immunocompromised individuals, regardless of age. 
• Susceptible adolescents and adults living in households with children.  
• Susceptible international travelers.     
• Residents and staff of institutional settings, including shelters, group homes, prisons 
and jails. 
Zoster 
(Shingles) 
All adults > 60 years* of age including: 
• Those in long-term care facilities 
• Those > 60 years anticipating immunodeficiency due to initiation of treatments or 
progression of illness (give > 14 days before treatment--some experts recommend 1 
month) 
• Persons with a prior episode of shingles  
• Persons with chronic medical conditions (e.g., renal failure, diabetes, rheumatoid 
arthritis) unless a contraindication or precaution exists for their condition. 
Note: Screening for a history of varicella disease, varicella vaccination or serologic testing is 
not recommended or necessary prior to administration of zoster vaccine. 
*Although zoster vaccine is licensed for use in those 50 years of age and older, the ACIP 
recommends that vaccination begin at 60 years of age. 
 
